|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM364872063 |
| 003 |
DE-627 |
| 005 |
20240410232312.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109845
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1371.xml
|
| 035 |
|
|
|a (DE-627)NLM364872063
|
| 035 |
|
|
|a (NLM)37995947
|
| 035 |
|
|
|a (PII)S1521-6616(23)00609-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Emmenegger, Marc
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.12.2023
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVES: COVID-19-associated coagulopathy, shown to increase the risk for the occurrence of thromboses and microthromboses, displays phenotypic features of the antiphospholipid syndrome (APS), a prototype antibody-mediated autoimmune disease. Several groups have reported elevated levels of criteria and non-criteria antiphospholipid antibodies (aPL), assumed to cause APS, during acute or post-acute COVID-19. However, disease heterogeneity of COVID-19 is accompanied by heterogeneity in molecular signatures, including aberrant cytokine profiles and an increased occurrence of autoantibodies. Moreover, little is known about the association between autoantibodies and the clinical events. Here, we first aim to characterise the antiphospholipid antibody, anti-SARS-CoV-2 antibody, and the cytokine profiles in a diverse collective of COVID-19 patients (disease severity: asymptomatic to intensive care), using vaccinated individuals and influenza patients as comparisons. We then aim to assess whether the presence of aPL in COVID-19 is associated with an increased incidence of thrombotic events in COVID-19
|
| 520 |
|
|
|a METHODS AND RESULTS: We conducted anti-SARS-CoV-2 IgG and IgA microELISA and IgG, IgA, and IgM antiphospholipid line immunoassay (LIA) against 10 criteria and non-criteria antigens in 155 plasma samples of 124 individuals, and we measured 16 cytokines and chemokines in 112 plasma samples. We additionally employed clinical and demographic parameters to conduct multivariable regression analyses within multiple paradigms. In line with recent results, we find that IgM autoantibodies against annexin V (AnV), β2-glycoprotein I (β2GPI), and prothrombin (PT) are enriched upon infection with SARS-CoV-2. There was no evidence for seroconversion from IgM to IgG or IgA. PT, β2GPI, and AnV IgM as well as cardiolipin (CL) IgG antiphospholipid levels were significantly elevated in the COVID-19 but not in the influenza or control groups. They were associated predominantly with the strength of the anti-SARS-CoV-2 antibody titres and the major correlate for thromboses was SARS-CoV-2 disease severity
|
| 520 |
|
|
|a CONCLUSION: While we have recapitulated previous findings, we conclude that the presence of the aPL, most notably PT, β2GPI, AnV IgM, and CL IgG in COVID-19 are not associated with a higher incidence of thrombotic events
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Antiphospholipid antibodies
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a Bayesian analysis
|
| 650 |
|
4 |
|a Cytokines
|
| 650 |
|
4 |
|a Epidemiology
|
| 650 |
|
4 |
|a Influenza
|
| 650 |
|
4 |
|a Innate immunity
|
| 650 |
|
4 |
|a Random forest regression
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
4 |
|a Virology
|
| 650 |
|
7 |
|a Antibodies, Antiphospholipid
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Anticardiolipin
|2 NLM
|
| 650 |
|
7 |
|a beta 2-Glycoprotein I
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Prothrombin
|2 NLM
|
| 650 |
|
7 |
|a 9001-26-7
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 700 |
1 |
|
|a Emmenegger, Vishalini
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shambat, Srikanth Mairpady
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Scheier, Thomas C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gomez-Mejia, Alejandro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chang, Chun-Chi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wendel-Garcia, Pedro D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Buehler, Philipp K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Buettner, Thomas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Roggenbuck, Dirk
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Brugger, Silvio D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Frauenknecht, Katrin B M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 257(2023) vom: 25. Dez., Seite 109845
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:257
|g year:2023
|g day:25
|g month:12
|g pages:109845
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109845
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 257
|j 2023
|b 25
|c 12
|h 109845
|